Biotechnology Barcelona, Spain-based plasma-derived medicine specialist Grifols says that its biotech subsidiary GigaGen has signed an agreement with the National Cancer Institute (NCI), part of the USA’s National Institutes of Health (NIH), to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564. 3 October 2023